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Jin‑Ok Jeong11, Ji Hyun Lee12,13* & Sang‑Hak Lee2*
Among the 146 patients enrolled in the Korean FH registry, 83 patients who had undergone 
appropriate LLT escalation and were followed‑up for ≥ 6 months were analyzed for pathogenic variants 
(PVs). The achieved percentage of expected low‑density lipoprotein‑cholesterol (LDL‑C) reduction 
(primary variable) and achievement rates of LDL‑C < 70 mg/dL were assessed. The correlations 
between the treatment response and the characteristics of PVs, and the weighted 4 SNP‑based score 
were evaluated. The primary variables were significantly lower in the PV‑positive patients than in 
the PV‑negative patients (p = 0.007). However, the type of PV did not significantly correlate with 
the primary variable. The achievement rates of LDL‑C < 70 mg/dL was very low, regardless of the 
PV characteristics. Patients with a higher 4‑SNP score showed a lower primary variable  (R2 = 0.045, 
p = 0.048). Among evolocumab users, PV‑negative patients or those with only defective PVs revealed 
higher primary variable, whereas patients with at least one null PV showed lower primary variables. 
The adjusted response of patients with FH to LLT showed significant associations with PV positivity 
and 4‑SNP score. These results may be helpful in managing FH patients with diverse genetic 
backgrounds.
Many patients with familial hypercholesterolemia (FH) are not diagnosed early enough to be treated properly 
and this has made it a global health  issue1–3. Pharmacological treatment for FH has made considerable progress 
in the past two decades. Currently, pharmacological agents including statins, ezetimibe, and PCSK9 inhibitors 
are used to treat FH in clinical  practice4,5. Clinical trials or registry studies conducted till date have reported that 
individual responses to lipid-lowering therapy (LLT) using  statins6 and/or PCSK9  inhibitors7–9 vary substantially. 
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Individual difference in response to LLT is a crucial clinical issue as it can affect cardiovascular  outcomes10. How-
ever, the reason underlying the variation in response to LLT among individuals is not yet completely understood.
Several  clinical11 and genetic  factors12 have been reported to influence the response in general population. 
Thus, in FH, it is likely that genetic variations affect an individual’s response to LLT. Differences in cardiovas-
cular risk due to genetic characteristics in  FH13,14 may be partly explained if the presence or type of pathogenic 
variants (PVs) influenced the patient response. Some studies have reported that the response to  statins15 and 
PCSK9  inhibitors16 could differ depending on PV types, such as defective PV. However, contradictory  studies8,17 
have warranted the need for further studies to clarify the link between genetic characteristics and responses to 
statins and PCSK9 inhibitors.
This study aimed to analyze the relationship between genetic characteristics and the response to LLT in 
patients with FH. The primary variable in our study was the achieved percentage of expected response to LLT. 
First, the expected low-density lipoprotein-cholesterol (LDL-C) reduction with an LLT regimen was estimated 
and then the achieved percentage of this expected value was calculated for each subject. The correlation of the 
4-SNP  score18 with the response was also investigated, and the difference in response according to genetic char-
acteristics was evaluated in patients receiving evolocumab.
Methods
Study population. Nine university hospitals participated in this study supported by the Korean Society of 
Lipid and  Atherosclerosis18–21. All subjects gave written informed consent, and all study protocols were approved 
by the institutional review board of Severance Hospital, Seoul, Korea. The study protocol conforms to the ethi-
cal guidelines of the 1975 Declaration of Helsinki. One hundred and forty-six men and women aged more than 
19 years who met the Simon-Broome  criteria22 for heterozygous FH were enrolled in the study conducted from 
January 2009 to July 2014. Among them, 83 patients who underwent proper escalation of LLT (described in ‘2.3. 
Parameters of response to LLT’) and followed up for ≥ 6 months, and for whom pre- and post-treatment LDL-C 
levels were known were finally analyzed. Among the 63 excluded patients, 31 did not receive appropriate LLT 
escalation, 18 were not followed-up for 6 months, whereas 14 did not undergo regular measurement of LDL-C.
Clinical and genetic data collection. Patient history was obtained from every patient, and each patient 
was subjected to physical examination and laboratory assessment. Patients under LLT at enrollment were asked 
to skip lipid-lowering agents for 4 weeks unless they had a history of atherosclerotic cardiovascular or cerebro-
vascular diseases. The patients fasted for 12 h before blood sampling, and the samples were analyzed within 4 h 
at a local laboratory. DNA sequencing and analysis for putative PVs was performed as described  previously20 
and in Supplementary Information.
According to the detection of non-synonymous variants by the Unified GATK Genotyper (v2.3.6), variants 
were classified as pathogenic based on the information regarding three FH-related genes on public databases. 
For variants that had not been previously reported, pathogenicity was confirmed based on one of the following: 
(1) inevitably deleterious effects of amino acid changes such as frame shift insertions/deletions and copy number 
deletions or (2) co-segregation of the same variants within the family. Thereafter, all variants listed as pathogenic 
were validated by Sanger sequencing. All variants were also checked by the MUTALYZER program. Finally, each 
variant was classified according to the American College of Medical Genetics and Genomics guidelines. Null 
PVs included point PVs that cause a premature stop codon, missense PVs affecting the fifth cysteine rich repeat 
in the ligand binding domain of LDLR, small deletions or insertions causing a frame shift, and a premature stop 
codon or large rearrangements. The remaining in-frame point PVs and in-frame small deletions and insertions 
consisted of receptor-defective  PVs13.
Parameters of response to LLT. When patients were enrolled in the study, LLT was initiated with moder-
ate intensity statins (i.e. rosuvastatin 5‒10 mg, atorvastatin 10‒20 mg, or other statins with a similar efficacy). If 
the statin was tolerated well, it was up-titrated every 2 months to reach an LDL-C level of 100 mg/dL. Ezetimibe 
was added if patients were intolerant to the statins or if the target LDL-C level was not achieved with the maxi-
mum tolerable dose of statin. Bile acid sequestrants, niacin, or PCSK9 inhibitors were administered to patients 
who did not show sufficient LDL-C reduction with statin/ezetimibe regimens. However, data only related to 
treatment responses for maximum statin dose with or without ezetimibe before introduction of other agents 
were used for the main analysis.
Pre-treatment LDL-C levels were defined as the documented values before drug therapy, whereas post-
treatment LDL-C levels were defined as the values obtained by a maximally up-titrated statin/ezetimibe regimen 
at 6‒12 months after drug treatment. The primary evaluation variable was the achieved percentage of expected 
LDL-C reduction. The expected LDL-C reduction was calculated using different doses of statins determined from 
previous studies and reviews (Table 1)23–29. Other evaluation variables included the percentage LDL-C reduction 
and achievement rate of an LDL-C target of < 70 mg/dL.
For additional six patients who received evolocumab in addition to the statin/ezetimibe regimens, the 
achieved percentage of expected LDL-C reduction was analyzed separately. The expected LDL-C reduction 
after addition of evolocumab to the regimen at a dose of 140 mg/2 weeks for 3 months was assumed to be 54%.
4‑SNP score. We genotyped the four SNPs associated with cholesterol levels in the FH patients and the 
general population in East  Asia18,30, i.e., rs651007, rs599839, rs12654264, and rs2738446 and are located close to 
ABO, CELSRS-PSRC1-SORT1, HMGCR , and LDLR, respectively. Weighted mean SNP scores of patients were 
calculated using alleles associated with cholesterol levels and their beta-coefficients, as reported in the East Asian 
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genome-wide association study (Supplementary Table 1. List of SNPs associated with elevated LDL-C levels in 
East Asians). The correlation between the 4-SNP score and the primary variable was analyzed.
Statistical analyses. Continuous data are presented as mean ± standard deviation or median (interquartile 
range), whereas categorical variables are reported as frequencies and percentages. Data related to clinical and 
laboratory values were compared using the chi-square test. Between-group comparisons were performed using 
the Mann‒Whitney U-test. Linear regression was used to assess the association between the 4 SNP score and 
treatment response in the PV-negative group. There were no missing data in this study. All analyses used a sig-
nificance level of 0.05. SPSS version 25.0 (SPSS Inc., Chicago, IL, USA) was used for the analyses.
Results
Clinical characteristics of the study population. The characteristics of the 83 patients enrolled in the 
study are presented in Table 2. The mean age of the patients was 53 years and 50 (60%) of them were women. 
Putative PVs were identified in 30 patients (36%) (Supplementary Table S2). The median baseline LDL-C was 
higher in the carriers of PVs compared to that in the PV-negative patients (246 mg/dL and 206 mg/dL, respec-
tively, p < 0.001). The median baseline LDL-C levels were 256 mg/dL, 248 mg/dL, and 205 mg/dL in patients with 
null LDLR PVs, defective LDLR PVs, and APOB or PCSK9 PVs, respectively. However, differences in LDL-C 
levels between individuals with different PV types were insignificant (Table 3). During the median follow-up 
period of 10 months, 40 (48%) patients were treated with statin monotherapy, whereas 43 (52%) received statin/
ezetimibe combination therapy (Table 2).
Genetic variants and response to LLT. In the total study population (n = 83), the median LDL-C 
decreased from 213 mg/dL to 105 mg/dL (median LDL-C reduction 51.9%). The primary variable, the achieved 
percentage of expected LDL-C reduction, was 89% and the achievement rate of LDL-C < 70 mg/dL was 6.0%. The 
distribution of the primary evaluation variable is shown in Supplementary Fig. 1 (Distribution of the achieved 
percentage of expected LDL-C reduction). The primary variable was significantly lower in the PV-positive 
patients than in the PV-negative patients (82.8% and 95.3%, respectively, p = 0.007). Although this variable was 
lower in patients with null LDLR PVs than in those with defective LDLR PV, the difference was not signifi-
cant (76.9% and 88.6%, respectively, p = 0.15). The primary variable was similar between carriers of LDLR PVs 
and those with PVs in the other two genes. Only four PV-negative patients and one with PCSK9 PV achieved 
LDL-C < 70 mg/dL (Table 3).
4‑SNP score and response to LLT. The correlation between the weighted mean of the 4-SNP score in the 
study population and the primary evaluation variable is presented in Fig. 1. Patients with a higher score showed 
a lower achieved percentage of expected LDL-C reduction  (R2 = 0.045, p = 0.048) (Fig. 1A). Interestingly, the cor-
relation between the 4-SNP score and the primary variable was stronger in the subgroup of patients without null 
PVs  (R2 = 0.080, p = 0.018) (Fig. 1B).
Genetic variants and response to evolocumab. Six additional patients enrolled and analyzed in the 
study received evolocumab for ≥ 3  months. One of the patients was PV-negative and the others had PVs in 
LDLR. The primary variable by evolocumab was 153.3% in the PV-negative patients, whereas it was 46.0% in the 
PV-positive patients. Two of the heterozygous patients had the same null PV in c.682G > T (p.E228X), and the 
primary evaluation variables were 27.5% and 39.7%, respectively. One heterozygous patient had an LDLR copy 
number variation and a primary variable of 52.2%. The primary variable for the other heterozygous patient with 
a defective LDLR PV was 140.9%. Among the two homozygous patients, one had one null and one defective PV 
and the other had two defective PVs. Interestingly, the achieved percentages of expected LDL-C reduction were 
quite different in these two individuals (34.0% and 141.8% in the former and the latter, respectively) (Table 4).
Table 1.  Expected LDL-C reduction by different doses of the lipid-lowering regimen. LDL-C low-density 
lipoprotein-cholesterol.
Lipid-lowering regimen Expected LDL-C reduction, %
Atorvastatin 10 mg or similar/day − 40
Atorvastatin 20 mg or similar/day − 46
Atorvastatin 40 mg or similar/day − 52
Atorvastatin 80 mg or similar/day − 56
Atorvastatin 20 mg/ezetimibe 10 mg/day − 61
Atorvastatin 40 mg/ezetimibe 10 mg/day − 66
Evolocumab 140 mg/2 weeks − 54 (additional)
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Discussion
The major findings of this study include the following. First, the adjusted response to LLT, the primary variable, 
was lower in carriers of PVs than in PV-negative patients. The type of PV did not significantly affect the primary 
variable. Second, individuals with a higher 4-SNP score showed a lower primary variable. Third, the primary 
variables for evolocumab-treated patients tended to be lower for PV-positive patients, particularly null PV car-
riers. We determined the response to LLT according to the adjusted percentage change of LDL-C by regimens 
titrated in the real world, and analyzed its correlation with the patient’s genotype. Prior studies analyzed response 
to non-maximal intensity  LLT31 or unadjusted response to drug  doses32. Furthermore, some investigators ana-
lyzed the response in a binary fashion according to the attainment of target LDL-C  levels15. We evaluated the 
relationship between polygenic score and adjusted drug response, which has not been previously reported. In 
addition, we reported the association between genotype and adjusted response to evolocumab, which has also 
been rarely discussed in previous studies. However, since the number of our cases on this issue was not large, 
further studies are needed.
The results of this study confirmed that the response to LLT is poorer in PV-positive patients. PV-positive 
patients with FH have been known to have higher cardiovascular risk than PV-negative  patients33. Therefore, 
genetic information in FH cases could enable risk evaluation, thereby ensuring rigorous management and treat-
ment for individuals with higher risk. Interestingly, 28 patients (33.7%) from our study population received just 
moderate intensity statins. In additional analysis, the LLT intensities used in the PV-negative group and the 
PV-positive group were found to be significantly different (p < 0.001) (Supplementary Table S3. LLT intensities 
used in the PV-negative and -positive patients). In particular, 27 (50.9%) of PV-negative patients used moderate 
intensity statins, whereas only one (3.3%) of PV-positive patients used moderate intensity statins.
Table 2.  Clinical and laboratory parameters of the study population. Data are presented as n (%), 
mean ± standard deviation, or median (interquartile range). Premature CAD is defined as CAD at 
age < 50 years in a grandparent, aunt, or uncle or at age < 60 years in a parent, sibling, or child. CAD coronary 
artery disease, FH familial hypercholesterolemia, PV pathogenic variant, HDL-C high-density lipoprotein-
cholesterol, LDL-C low-density lipoprotein-cholesterol.
Variables Value or frequency (total subjects = 83)
Age, years 53 ± 12
Females 50 (60.2)
Medical history
Diabetes mellitus 6 (7.2)
Hypertension 30 (36.1)




Premature CAD 42 (50.6)
Physical findings
Body mass index, kg/m2 24.7 ± 4.5
Tendon xanthoma 17 (20.5)
Type of FH in clinical diagnosis
Definite 18 (21.7)
Possible 65 (78.3)
PV positivity 30 (36.1)
Lipid profile, mg/dL
Total cholesterol 307 (287, 341)
Triglyceride 149 (116, 227)
HDL-C 46 (40, 56)
LDL-C 213 (198, 248)
Maximal statin-based lipid-lowering regimen
Atorvastatin 10 mg or similar 6 (7.2)
Atorvastatin 20 mg or similar 22 (26.5)
Atorvastatin 40 mg or similar 7 (8.4)
Atorvastatin 80 mg or similar 5 (6.0)
Atorvastatin 20 mg/ezetimibe 10 mg or similar 10 (12.0)
Atorvastatin 40 mg/ezetimibe 10 mg or similar 21 (25.3)
Atorvastatin 80 mg/ezetimibe 10 mg or similar 12 (14.5)
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Table 3.  Genetic background and response to LLT with a statin/ezetimibe regimen. Data are presented as 
median (interquartile range) or number (%). pa: comparison between PV-positive and -negative patients. 
pb: comparison between LDLR PV and APOB or PCSK9 PV carriers. pc: comparison between null LDLR 










LDLR mutation (n = 27) APOB or PCSK9 
PV
(n = 3)
Any LDLR PV 
(n = 27)
Null LDLR PV 
(n = 10)
Defective LDLR 








114 (96, 131) 105 (88, 125) 122 (110, 138) 122 (114, 139) 133 (123, 143) 119 (110, 137) 97 (69, –) 0.012 0.13 0.059
LDL-C reduc-
tion, % 51.9 (41.9, 57.3) 50.7 (42.2, 55.6) 50.7 (39.5, 58.4) 50.4 (39.4, 58.8) 49.9 (44.8, 54.4) 51.0 (39.4, 61.2) 59.1 (24.1, –) 0.82 0.56 0.48
LDL-C reduction 
% of expected 
value




5 (6.0) 4 (7.5) 1 (3.3) 0 (0) 0 (0) 0 (0) 1 (33.3) 0.44 0.003 1.00
Figure 1.  Correlation between the weighted 4-SNP score and the achieved percentage of expected LDL-C 
reduction in all study patients (A) and patients without null PVs (B). The image was created using GraphPad 
Prism version 8.4.3 for Windows (GraphPad Software, San Diego, CA, USA; www.graph pad.com).
Table 4.  Genetic background and response to LLT with evolocumab. Data are presented as a number, 
percentage, or median (interquartile range). LLT lipid-lowering therapy, PV pathogenic variant, LDL-C low-
density lipoprotein-cholesterol, CNV copy number variation.
PV-negative (n = 1)
PV-positive (n = 6)
Any PV-positive 
(n = 6)
Heterozygous PV (n = 4) Homozygous PV (n = 2)
c.682G > T 
(p.E228X) 
(n = 2)
CNV, exon 8–12 
(n = 1)
c.519C > G (C173W) 
(n = 1)
G558X and
c.-136C > T (n = 1)
c.1567G > A (V523M) 
and c.-136C > T (n = 1)
Pre-evolocuamb LDL-
C, mg/dL 157 154 (135, 327) 169 126 138 138 410 299
Post-evolocuamb 
LDL-C, mg/dL 27 103 (61, 194) 149 99 107 33 329 70
LDL-C reduction, % 82.8 21.9 (17.8, 76.2) 11.8 21.4 22.5 76.1 19.8 76.6
LDL-C reduction, % of 
expected value 153.3 46.0 (32.4, 141.1) 27.5 39.7 52.2 140.9 34.0 141.8
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The median percentage change of LDL-C was − 51.9% in our total study population. In clinical trials with 
heterozygous FH patients, the values were − 49% by pitavastatin 4 mg34 and − 46 to − 51% by simvastatin 80 mg35. 
However, in real world data of patients receiving statins with or without ezetimibe, the values varied from − 3636 
to − 50%37. The percentage change of LDL-C of our study was relatively large in our study. However, it is difficult 
to directly compare these values, as therapeutic regimens were heterogenous in individual studies, and data on 
the relationship between LLT intensities and responses have not been shown. This is one of the reasons why we 
used an adjusted parameter of response to LLT.
In the present study, we compared primary variables according to types of PVs. Although the variables were 
numerically lower in null LDLR PV carriers than those in defective LDLR PV carriers, the difference was not 
significant. However, we cannot fully rule out the fact that this might have been significant had the study incor-
porated a larger number of patients. In a previous study, patients with null PVs had higher LDL-C levels before 
and after LLT as compared to those with defective  PVs38 and lower rates of target achievement independent of 
the statin  dose32. Furthermore, in a relatively large study conducted on Spanish patients, the presence of defec-
tive PVs was found to be an independent predictor of achievement of LDL-C  goal15. In another study, LDL-C 
reduction with atorvastatin, 20 mg/day was observed to vary among different classes of LDLR PVs (49% and 34% 
for class V and class II PVs, respectively)31. Another study revealed that heterozygous FH patients with defective 
LDLR PVs showed a better response to statin/ezetimibe-based LLT than homozygous FH patients with defective 
LDLR  PVs39. However, data related to the response to LLT based on types of PVs are inconsistent, as indicated 
by a previous  study40, and are not fully understood yet. In a previous study on homozygous FH patients, mean 
LDL-C reduction by rosuvastatin 20 mg/day was not much different between carriers of defective/negative PVs 
and those of defective/defective PVs (17.0% and 21.3%, respectively)17.
To the best of our knowledge, this study is the first to identify the association between the 4-SNP score and 
the response to LLT. SNPs that correlated with LDL-C levels in Korean patients with FH in our prior  study18 
were used for the score. A few variants of SLCO1B1, SLCO1B3, and ABCC2 have been reported to be correlated 
with the response to  statins41 in Koreans, and this correlation has been linked to pharmacodynamic pathways. 
In addition, a common loss-of-function variant of PCSK9 showed an association with greater response to statins 
in an American  study42. The Heart Protection Study and a meta-GWAS demonstrated that variants of SORT1/
CELSR2/PSRC1, SLCO1B1, APOE, and LPA are associated with the response to  statins12,43. The 4-SNP score in 
this study includes SORT1, CELSR2, and PSRC1, and the effect of their corresponding variants contributes to 
the agreement of our findings with those of previous studies.
The present study showed that the presence of a null PV could affect the response to evolocumab regardless 
of the homozygosity of PVs. Prior data related to the effect of genotype on the response to PCSK9 inhibitors have 
been variable. An analysis of six studies using alirocumab, a PCSK9 inhibitor, revealed that LDL-C reduction 
was generally similar across genotypes (54.3% and 60.7% in defective LDLR- and negative LDLR PV carriers, 
respectively)8. In addition, a recent report on homozygous FH has shown that the response to alirocumab in 
defective/negative LDLR PV carriers was not worse than that in defective/defective LDLR PV  carriers44. On the 
contrary, in this study, the response to evolocumab was higher than expected in heterozygous FH with defective 
PVs and in homozygous FH with defective/defective PVs. However, the response in heterozygous and homozy-
gous patients with null PVs was poor. These findings indicate that the influence of null PVs can be greater than 
that of homozygosity of PVs. A recent study evaluated the long-term effect of evolocumab in homozygous and 
severe heterozygous FH. Although the relationship between genotype and drug efficacy was not the main focus 
of this study, reduced efficacy of the agent was observed in patients with two negative LDLR  PVs9.
Our study, however, has potential limitations. First, while the current study used a 4-SNP score, the effect of 
other SNPs of the same genes or other lipid-related genes cannot be ruled out. Second, because this study was 
performed using data from Korea, we need to be cautious when generalizing our results. Third, we cannot rule out 
some difference between patient groups that was not revealed in the current data. For example, median baseline 
LDL-C levels did not differ according to PV types. However, these were derived in part from limited number of 
patients with APOB or PCSK9 PVs that usually constitute a small minority of FH patients. However, adjustment 
of the response to LLT by calculating the achieved percentage of expected LDL-C is the strength of this study.
In conclusion, our findings indicate that adjusted response to LLT has significant associations with PV posi-
tivity and the 4-SNP score. The results obtained in this study may ensure effective and individual management 
of FH patients with diverse genetic backgrounds.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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